Steiger Katja, Schlitter Anna-Melissa, Weichert Wilko, Esposito Irene, Wester Hans-Jürgen, Notni Johannes
1 Institute of Pathology, Technische Universität München, Munich, Germany.
2 German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany.
Mol Imaging. 2017 Jan 1;16:1536012117709384. doi: 10.1177/1536012117709384.
ß-integrin immunohistochemistry analysis of a large number of pancreatic ductal adenocarcinoma (PDAC, 383 primary tumors, 7 lymph node, and 8 distant metastases) and 34 pancreatic intraepithelial neoplasia (PanIN) specimens revealed a high prevalence of αß-integrin expression in PDAC primaries (88%) and in almost all metastases, as well as in PanIN (57%). These findings underscore the high potential of a novel αß-integrin targeting positron emission tomography (PET) radiopharmaceutical, Ga-68-Avebehexin, for early diagnosis of pancreatic cancer.
对大量胰腺导管腺癌（PDAC，383例原发性肿瘤、7例淋巴结转移和8例远处转移）以及34例胰腺上皮内瘤变（PanIN）标本进行的β整合素免疫组化分析显示，αβ整合素在PDAC原发性肿瘤（88%）、几乎所有转移灶以及PanIN（57%）中均有高表达。这些发现凸显了一种新型的靶向αβ整合素的正电子发射断层扫描（PET）放射性药物Ga-68-Avebehexin在胰腺癌早期诊断方面的巨大潜力。
